APRE
Price
$1.66
Change
+$0.09 (+5.73%)
Updated
Oct 20, 04:59 PM (EDT)
Capitalization
9.61M
Intraday Buy/Sell Signals
WVE
Price
$7.81
Change
-$0.00 (-0.00%)
Updated
Oct 20, 04:59 PM (EDT)
Capitalization
1.24B
17 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

APRE vs WVE

Header iconAPRE vs WVE Comparison
Open Charts APRE vs WVEBanner chart's image
Aprea Therapeutics
Price$1.66
Change+$0.09 (+5.73%)
Volume$20.83K
Capitalization9.61M
Wave Life Sciences
Price$7.81
Change-$0.00 (-0.00%)
Volume$68.13K
Capitalization1.24B
APRE vs WVE Comparison Chart in %
APRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WVE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APRE vs. WVE commentary
Oct 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APRE is a Hold and WVE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 21, 2025
Stock price -- (APRE: $1.57 vs. WVE: $7.81)
Brand notoriety: APRE and WVE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APRE: 339% vs. WVE: 81%
Market capitalization -- APRE: $9.15M vs. WVE: $1.24B
APRE [@Biotechnology] is valued at $9.15M. WVE’s [@Biotechnology] market capitalization is $1.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APRE’s FA Score shows that 2 FA rating(s) are green whileWVE’s FA Score has 0 green FA rating(s).

  • APRE’s FA Score: 2 green, 3 red.
  • WVE’s FA Score: 0 green, 5 red.
According to our system of comparison, APRE is a better buy in the long-term than WVE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APRE’s TA Score shows that 5 TA indicator(s) are bullish while WVE’s TA Score has 3 bullish TA indicator(s).

  • APRE’s TA Score: 5 bullish, 3 bearish.
  • WVE’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, APRE is a better buy in the short-term than WVE.

Price Growth

APRE (@Biotechnology) experienced а +10.56% price change this week, while WVE (@Biotechnology) price change was +2.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was +18.12%, and the average quarterly price growth was +72.90%.

Reported Earning Dates

WVE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+4.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
WVE($1.24B) has a higher market cap than APRE($9.61M). WVE YTD gains are higher at: -36.863 vs. APRE (-52.280). APRE has higher annual earnings (EBITDA): -14.77M vs. WVE (-134.84M). WVE has more cash in the bank: 208M vs. APRE (16.5M). APRE has less debt than WVE: APRE (0) vs WVE (21.7M). WVE has higher revenues than APRE: WVE (93.9M) vs APRE (0).
APREWVEAPRE / WVE
Capitalization9.61M1.24B1%
EBITDA-14.77M-134.84M11%
Gain YTD-52.280-36.863142%
P/E RatioN/AN/A-
Revenue093.9M-
Total Cash16.5M208M8%
Total Debt021.7M-
FUNDAMENTALS RATINGS
APRE vs WVE: Fundamental Ratings
APRE
WVE
OUTLOOK RATING
1..100
2535
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6252
P/E GROWTH RATING
1..100
4100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APRE's Valuation (14) in the null industry is somewhat better than the same rating for WVE (49) in the Biotechnology industry. This means that APRE’s stock grew somewhat faster than WVE’s over the last 12 months.

APRE's Profit vs Risk Rating (100) in the null industry is in the same range as WVE (100) in the Biotechnology industry. This means that APRE’s stock grew similarly to WVE’s over the last 12 months.

APRE's SMR Rating (98) in the null industry is in the same range as WVE (100) in the Biotechnology industry. This means that APRE’s stock grew similarly to WVE’s over the last 12 months.

WVE's Price Growth Rating (52) in the Biotechnology industry is in the same range as APRE (62) in the null industry. This means that WVE’s stock grew similarly to APRE’s over the last 12 months.

APRE's P/E Growth Rating (4) in the null industry is significantly better than the same rating for WVE (100) in the Biotechnology industry. This means that APRE’s stock grew significantly faster than WVE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APREWVE
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
87%
Momentum
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
78%
MACD
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 6 days ago
77%
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
84%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
APRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WVE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PTHL0.630.03
+4.46%
Pheton Holdings Ltd
WU8.290.21
+2.60%
Western Union Company (The)
SNA339.75-4.42
-1.28%
Snap-on
FUFU3.60-0.09
-2.44%
BitFuFu
MATH2.87-0.11
-3.69%
Metalpha Technology Holding Limited

APRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, APRE has been loosely correlated with CABA. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if APRE jumps, then CABA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APRE
1D Price
Change %
APRE100%
+1.95%
CABA - APRE
33%
Loosely correlated
-1.04%
PRQR - APRE
32%
Poorly correlated
-0.71%
ATOS - APRE
32%
Poorly correlated
-4.89%
EYPT - APRE
31%
Poorly correlated
+0.69%
WVE - APRE
30%
Poorly correlated
-0.76%
More